| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| X0621 |
|
2,562 |
1,846 |
$511K |
| 87481 |
|
4,493 |
3,862 |
$280K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
6,757 |
6,342 |
$260K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
6,910 |
6,638 |
$174K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
6,035 |
5,765 |
$138K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
546 |
531 |
$136K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
1,253 |
1,236 |
$105K |
| 87150 |
|
2,250 |
2,210 |
$91K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
2,650 |
2,590 |
$78K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
1,764 |
1,728 |
$68K |
| 87631 |
|
377 |
357 |
$51K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
5,436 |
5,280 |
$44K |
| 87511 |
|
1,811 |
1,754 |
$35K |
| 17110 |
|
733 |
717 |
$32K |
| T1015 |
Clinic visit/encounter, all-inclusive |
1,024 |
892 |
$30K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,809 |
1,661 |
$25K |
| 86803 |
|
1,164 |
1,137 |
$22K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
643 |
638 |
$18K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
232 |
232 |
$18K |
| 81025 |
|
4,309 |
4,151 |
$17K |
| 11721 |
|
1,355 |
1,330 |
$17K |
| 76830 |
Ultrasound, transvaginal |
290 |
264 |
$17K |
| 96900 |
|
680 |
165 |
$17K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,141 |
1,015 |
$16K |
| 84443 |
Thyroid stimulating hormone (TSH) |
688 |
672 |
$16K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,014 |
1,001 |
$14K |
| 73630 |
|
995 |
732 |
$13K |
| 90715 |
|
1,510 |
1,499 |
$12K |
| 81513 |
|
205 |
201 |
$12K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,258 |
1,238 |
$12K |
| 11102 |
|
393 |
380 |
$11K |
| 80053 |
Comprehensive metabolic panel |
866 |
840 |
$10K |
| 82570 |
|
1,317 |
1,261 |
$10K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
73 |
70 |
$9K |
| 85027 |
|
1,123 |
1,088 |
$8K |
| 86762 |
|
388 |
386 |
$8K |
| Q3014 |
Telehealth originating site facility fee |
554 |
549 |
$8K |
| J7298 |
Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
15 |
12 |
$7K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,251 |
1,237 |
$7K |
| 87340 |
|
462 |
461 |
$7K |
| 86850 |
|
750 |
743 |
$6K |
| 11057 |
|
270 |
263 |
$6K |
| 88312 |
|
99 |
95 |
$6K |
| 80081 |
|
72 |
70 |
$6K |
| 77066 |
Tomosynthesis, mammo |
66 |
66 |
$5K |
| G0008 |
Administration of influenza virus vaccine |
577 |
572 |
$5K |
| 84156 |
|
1,267 |
1,213 |
$5K |
| 82728 |
|
435 |
429 |
$5K |
| 84702 |
|
303 |
267 |
$5K |
| 90686 |
|
428 |
424 |
$5K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
232 |
232 |
$5K |
| 86592 |
|
1,140 |
1,125 |
$5K |
| 87430 |
|
740 |
718 |
$5K |
| 71046 |
Radiologic examination, chest; 2 views |
235 |
230 |
$4K |
| 36415 |
Collection of venous blood by venipuncture |
2,932 |
2,771 |
$4K |
| 76642 |
|
109 |
88 |
$4K |
| 86901 |
|
843 |
762 |
$4K |
| 86900 |
|
842 |
762 |
$4K |
| 80061 |
Lipid panel |
266 |
263 |
$4K |
| 83540 |
|
433 |
426 |
$4K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
47 |
47 |
$3K |
| 11900 |
|
32 |
32 |
$3K |
| 11056 |
|
167 |
166 |
$3K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
36 |
36 |
$3K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
55 |
55 |
$3K |
| G0101 |
Cervical or vaginal cancer screening; pelvic and clinical breast examination |
65 |
64 |
$3K |
| 77065 |
Tomosynthesis, mammo |
44 |
44 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
63 |
63 |
$3K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
963 |
958 |
$2K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
251 |
247 |
$2K |
| 83550 |
|
424 |
418 |
$2K |
| 88341 |
|
25 |
25 |
$2K |
| 76801 |
|
41 |
41 |
$2K |
| 86780 |
|
134 |
133 |
$2K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
98 |
77 |
$2K |
| 82950 |
|
293 |
288 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
290 |
288 |
$2K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
99 |
99 |
$2K |
| J2791 |
Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu |
30 |
30 |
$2K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
49 |
48 |
$1K |
| 82607 |
|
109 |
108 |
$1K |
| 87186 |
|
150 |
146 |
$1K |
| 88342 |
|
28 |
27 |
$1K |
| 85046 |
|
176 |
171 |
$1K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
15 |
15 |
$973.70 |
| 73610 |
|
31 |
29 |
$804.52 |
| 81003 |
|
263 |
263 |
$791.85 |
| 17000 |
|
55 |
54 |
$729.90 |
| 84146 |
|
27 |
27 |
$671.20 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
72 |
72 |
$667.06 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
216 |
196 |
$645.23 |
| 88304 |
|
63 |
55 |
$594.56 |
| 82746 |
|
46 |
45 |
$543.36 |
| 87101 |
|
54 |
53 |
$521.44 |
| 88142 |
|
29 |
29 |
$452.64 |
| 90656 |
|
175 |
175 |
$423.48 |
| 82565 |
|
62 |
58 |
$375.78 |
| 84439 |
|
45 |
45 |
$374.16 |
| 85610 |
|
75 |
73 |
$239.12 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
276 |
268 |
$226.20 |
| 58300 |
|
13 |
13 |
$217.38 |
| 87206 |
|
73 |
72 |
$214.14 |
| 86038 |
|
13 |
13 |
$206.25 |
| 51798 |
|
14 |
14 |
$173.88 |
| 85730 |
|
26 |
26 |
$166.02 |
| 82043 |
|
13 |
13 |
$109.04 |
| 85652 |
|
36 |
36 |
$103.44 |
| 87088 |
|
12 |
12 |
$101.28 |
| 87077 |
|
13 |
13 |
$95.68 |
| 84478 |
|
12 |
12 |
$90.64 |
| 86140 |
|
18 |
18 |
$54.69 |
| 90678 |
|
63 |
63 |
$0.00 |